<DOC>
	<DOC>NCT00880308</DOC>
	<brief_summary>This first-in-human dose-escalation study is to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of LDE225 given orally on a daily dosing schedule in patients with advanced solid tumors.</brief_summary>
	<brief_title>Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Basal Cell</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<criteria>confirmed diagnosis of advanced solid tumor (including â€¢medulloblastoma and basal cell carcinoma) blood work criteria patients with history of brain tumor (except recurrent medulloblastoma) or brain metastases positive HIV, hepatitis B or C impaired intestinal function impaired heart function pregnant or breastfeeding women Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Advanced tumors</keyword>
	<keyword>hedgehog</keyword>
	<keyword>smoothened inhibitor</keyword>
</DOC>